Replies to post #21830 on Cel Sci Corporation (CVM)

[Fosco1]

Kpauliukonis
While your post has passed almost unnoticed, it should be of utmost importance for those who should think about investing in Cel SCI
I don't know if your questions was inspired from my original ideas regarding HPV prevalence and developing countries SOC
(here : Fosco View on trial Population)
but the answer of your ENT goes exactly where my conclusions go as well
This is all good for the trial outcome
I am not expecting a five years SoC observed OS above 55% in the best case in the blend of patients of this pIII trial